Episode 70: Matthias von Herrath, MD, Professor at the La Jolla Institute for Immunology and Vice President and Senior Medical Officer at Novo Nordisk

<p>In this episode, Dr. Matthias von Herrath joins us to discuss his work at the La Jolla Institute for Immunology and at pharmaceutical company Novo Nordisk. He discusses one of his recently published papers, "Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial". </p> <p>Full paper link: <a href='https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00019-X/fulltext'>https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00019-X/fulltext</a> </p>